EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke

H. Bart van der Worp1*, Malcolm R. Macleod2, Philip M. W. Bath3, Jacques Demotes4, Isabelle Durand-Zaleski5, Bernd Gebhardt6, Christian Gluud7, Rainer Kollmar8, Derk W. Krieger9, Kennedy R. Lees10, Carlos Molina11, Joan Montaner12, Risto O. Roine13, Jesper Petersson14, Dimitre Staykov15, Istvan Szabo16, Joanna M. Wardlaw17, Stefan Schwab15, and on behalf of the EuroHYP-1 investigators†

Rationale Cooling reduced infarct size and improved neurological outcomes in animal studies modeling ischemic stroke, and also improved outcome in randomized clinical trials in patients with hypoxic-ischemic brain injury after cardiac arrest. Cooling awake patients with ischemic stroke has been shown feasible in phase II clinical trials. **Primary aim** To determine whether systemic cooling to a target body temperature between 34·0 and 35·0°C, started within six-hours of symptom onset and maintained for 24 h, improves functional outcome at three-months in patients with acute ischemic stroke. **Design** International, multicenter, phase III, randomized, open-label clinical trial with blinded outcome assessment in 1500 patients aged 18 years or older with acute ischemic stroke and a National Institutes of Health Stroke Scale score of 6 up to and including 18. In patients randomized to hypothermia, cooling to a target body temperature of 34·0–35·0°C will be started within six-hours after symptom onset with rapid intravenous infusion of refrigerated normal saline or a surface cooling technique and maintained for 24 h with a surface or endovascular technique. Patients randomized to hypothermia will receive pethidine and buspirone to prevent shivering and discomfort. **Primary outcome** Score on the modified Rankin Scale at 91 days, as analyzed with ordinal logistic regression and expressed as a common odds ratio. **Discussion** With 750 patients per intervention group, this trial has 90% power to detect 7% absolute improvement at the 5% significance level. The full trial protocol is available at http://www.eurohyp1.eu. ClinicalTrials.gov Identifier: NCT01833312. Key words: acute stroke therapy, clinical trial, hypothermia, ischemic stroke, treatment.


Correspondence: H. R. van der Worp*, Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail: h.b.vanderworp@umcutrecht.nl

1Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, CX Utrecht, The Netherlands
2Division of Clinical Neurosciences, University of Edinburgh, Royal Infirmary of Edinburgh, UK
3Stroke, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
4Inserm, Institut de Santé Publique, Paris, France
5Department of Public Health, AP-HP, Henri Mondor-Albert Chenevier Hospitals, Creteil, France
6Center for Clinical Studies, Erlangen, Germany
7The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark
8Clinic for Neurology and Neurogeriatrics, Darmstadt, Germany
9Department of Neurology, Stroke Center, Copenhagen University Hospital, Copenhagen, Denmark
10Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
11Stroke Unit, Hospital Vall d’Hebron, Barcelona, Spain
12Neurovascular Research Laboratory, Department of Neurology, Hospital Vall d’Hebron, Barcelona, Spain
13Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland
14Department of Neurology, Skåne University Hospital, Malmö, Sweden
15Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany
16European Stroke Research Network for Hypothermia, Brussels, Belgium
17Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK

Received: 2 December 2013; Accepted: 31 March 2014; Published online 15 May 2014

†EuroHYP-1 investigators


Data Safety and Monitoring Committee: P.M.W. Bath (chair), G.D. Murray, P.S. Scutt (unblinded statistician), F. Sierz.


Ethics Board: B. Heinrichs, N.E. Sahlin (chair), P. Sandoe.

Trial coordination: B. Colam, A. Stilper, N. Votruba.
**Introduction and rationale**

In patients with acute ischemic stroke, early intravenous thrombolysis with alteplase, the administration of aspirin, decompressive surgery, and stroke unit care are the only treatments of proven benefit (1). Even if treatments are combined, about half of the patients remain dependent or die (2). For this reason, there is a clear need for additional, effective therapeutic strategies.

In animal studies modeling ischemic stroke, cooling to 35°C reduced infarct size by about one-third, and cooling to 34°C by around 45% (3). Several prospective observational clinical studies in stroke have shown an association between raised body temperature and poor outcome (4). Finally, cooling improved outcome in randomized trials in patients with hypoxic-ischemic brain injury after cardiac arrest (5). Next to novel reperfusion strategies, hypothermia is therefore a promising treatment for patients with acute ischemic stroke.

Systematic review and meta-analysis of therapeutic hypothermia for any indication strongly suggests an association between cooling and the risk of pneumonia and sepsis. No increase in the risk of any infection was observed when cooling was used to treat ischemic stroke, but the number of patients treated was small (6). In phase II trials, cooling awake patients with ischemic stroke has been shown feasible and safe (7–10), but whether this improves functional outcome has not yet been tested in an adequately-sized randomized clinical trial.

The primary objective of EuroHYP-1 is to determine whether systemic cooling to a target body temperature between 34-0 and 35-0°C, started within six hours of symptom onset and maintained for 24 h, improves functional outcome at three months in patients with acute ischemic stroke.

**Methods**

**Design**

This is an international, multicenter, randomized, parallel-group, open-label clinical superiority trial with blinded outcome assessment, registered at ClinicalTrials.gov as NCT01833312. The trial will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization-Good Clinical Practice and applicable regulatory requirements.

**Eligibility**

Patients may be enrolled in the trial if all of the inclusion criteria listed in Table 1 have been met but will be excluded from participation for any of the reasons listed in Table 2.

**Treatment allocation**

After enrollment, patients will be allocated to hypothermia plus best medical treatment or best medical treatment alone based on proportional minimization through a web-based allocation service. Treatment allocation will be stratified by country and will include the following minimization factors: intention to give alteplase; intended method of cooling (surface or endovascular); gender; stroke severity [National Institutes of Health Stroke Scale (NIHSS) 6–12 or 13–18]; age (≤65 years or >65 years); visibility of a relevant ischemic lesion on the first brain imaging (yes or no), and time since symptom onset (≤6 h or 6–12 h).

**Treatment**

In patients randomized to hypothermia, cooling will be started within six hours after onset of symptoms and within 90 mins of start of thrombolysis (or within 90 mins of hospital admission in patients who are not treated with thrombolysis) with intravenous infusion of 20 ml/kg refrigerated normal saline (4°C) over 30–60 mins or a surface cooling method, depending on local practice or preference. Cooling will be maintained at 34–35°C for 24 h with a surface or endovascular technique. The choice of this technique is at the discretion of the local investigator. Thereafter, patients will be passively warmed at a rate of 0.2 ± 0.1 °C per hour until the rectal or bladder temperature reaches 36–0°C; the cooling device will then be disconnected.

In patients randomized to hypothermia, shivering and discomfort will be prevented and treated with intravenous pethidine (max 500 mg/24 h) and oral buspironone (max 30 mg/24 h). The maximum dose of pethidine is about half that administered in previous trials targeting a body temperature of 33°C for 24 h (8,9) but higher than the dose of 2·3 mg/kg used in a recent surface cooling trial targeting a body temperature of 35°C for 12 h (10). In the last trial, pethidine was combined with intravenous dexmedetomidine. Patients who have difficulties swallowing will not receive buspironone unless they have a nasogastric tube. In one animal study of focal cerebral ischemia, pethidine did not affect the effects of hypothermia (11). For the prevention of

---

**Table 1 Inclusion criteria**

- Diagnosis of acute ischemic stroke.
- Age ≥18 years.
- NIHSS score of 6 up to and including 18.
- GCS motor response sub-scale score ≥ 5.
- mRS score ≤ 2 prior to onset of stroke.
- Estimated body weight of 50 up to and including 120 kg.
- Possibility to start therapeutic hypothermia within six hours after onset of stroke.
- Possibility to start therapeutic hypothermia within 90 mins after start of alteplase administration in patients receiving thrombolysis.
- Possibility to start therapeutic hypothermia within 90 mins after admission to trial site in patients not receiving thrombolysis.
- Written informed consent obtained from the patient or his/her legally acceptable representative or under such other arrangements as may be legally established in participating countries.
opioid-induced nausea and vomiting, ondansetron or granisetron is recommended.

In both intervention groups, patients will be treated according to published guidelines for the treatment of acute ischemic stroke and for secondary prevention.

Outcomes
The primary outcome is the score on the modified Rankin Scale (mRS) at 91 (±14) days, as analyzed with ordinal logistic regression and expressed as a common odds ratio. Secondary outcomes include death or dependency (mRS > 2), death, and scores on the NIHSS, EQ-5D-5L, and WHODAS 2-0 at 91 (±14) days, and infarct size, growth, swelling, and hemorrhagic transformation on repeat brain imaging with computed tomography or magnetic resonance imaging at 48 h (±24). Blood biomarker levels will be assessed in venous blood drawn before start of trial treatment and at 24 and 72 h after randomization. These biomarkers include – but are not limited to – gelatinases, collagenases, stromelysines, D-dimer, and C-reactive protein. An economic evaluation including a comparison of costs and an incremental cost-utility analysis will be performed.

To allow blinded assessment of the primary outcome and to enhance statistical power, the mRS at 91 days will be assessed by at least four independent adjudicators based on a video clip of the mRS interview, without reference to treatment allocation, coordinated from the University of Glasgow (12).

Sample size
A total of 1474 patients is required to detect an absolute reduction in the risk of death or disability (mRS > 2) of 7% (corresponding to an odds ratio of 0·74) with 90% power at the 5% significance level (two sided) and allowing for 3% loss to follow-up. This target sample size is rounded to 1500 patients.

Statistical analyses
The primary and secondary outcomes will be analyzed using the intention-to-treat population. The effect of the intervention on the primary outcome will also be studied in specific sub-groups, including those used as minimization factors at the time of randomization. Additional exploratory analyses will be based on the per-protocol population. The primary efficacy variable will be analyzed with ordinal logistic regression and expressed as a common odds ratio. The analysis will be adjusted for the minimization factors mentioned above. If the assumption of the ordinal regression analysis model is not fulfilled, the groups will be compared using a nonparametric method and that result will be the primary result. The secondary outcomes and safety variables will be analyzed with logistic regression, a general linear

---

Table 2 Exclusion criteria

- Evidence from CT or MRI of intracranial hemorrhage or tumour or encephalitis or any diagnosis likely to cause the present symptoms other than acute ischemic stroke. Hemorrhagic transformation of the infarct is not an exclusion criterion, except when there is a parenchymal hematoma covering more than 30% of the infarcted area, with significant space-occupying effect, or when there is a bleeding remote from the infarcted area.
- Rapidly resolving stroke symptoms.
- Use of monoaminoxidase inhibitors in the 14 days prior to screening.
- Current use of medication interacting with pethidine or buspirone.
- Acute alcohol intoxication.
- Opioid addiction.
- Nursing mother or pregnant woman, as verified by a positive urine pregnancy test in females of childbearing potential.
- Known hypersensitivity to the investigational medicinal products or any of their formulation ingredients.
- Any acutely life-threatening conditions other than acute ischemic stroke.
- Known convulsive disorder, acute closed angle glaucoma, myasthenia gravis.
- SPO₂ < 94% (as measured by pulse oximetry) under nasal oxygen administration.
- Other severe respiratory disorder.
- Bradycardia (<40 bpm).
- Severe cardiac failure, defined as NYHA classification ≥ III.
- Myocardial infarction or angina pectoris in the three months prior to screening.
- Vasoplastic disorders.
- Haematological dyscrasia.
- Known platelet count < 100 000/mm³.
- Known INR > 1.7.
- Skin damage at the sites intended to be used for cooling.
- Clinical diagnosis of sepsis.
- Known severe hepatic impairment (serum ALAT and/or ASAT > 3 times ULN).
- Known renal impairment (serum creatinine > 2 mg/100 ml).
- Addison’s disease.
- Any other condition that may interfere with, or be aggravated by, therapeutic hypothermia.
- Any condition that is thought to reduce the compliance to cooperate with the trial procedures.
- Patient who is imprisoned or is lawfully kept in an institution.
- Employee or direct relative of an employee of the CRO (if applicable), the department of the investigator, or the sponsor.
- Participation in an interventional clinical trial within the last 4 weeks, or be under the exclusion period from another trial.
- Prior participation in this trial.
univariate model, or a nonparametric test, where appropriate. A detailed statistical analysis plan will be published separately before data will be analyzed.

Data Safety and Monitoring Committee (DSMC)

An independent DSMC has been established to monitor the safety of the patients in the EuroHYP-1 trial by reviewing the available clinical data after 50, 100, 200, 400, 800, and 1200 patients have been recruited and followed up until the final assessment at 91 days and *ad hoc* as needed. With respect to efficacy and hazard, the DSMC will conduct interim analyses on partially cleaned data after the final assessment of the first 400 and 800 patients. Details are defined in a DSMC charter.

Study organization

The University of Erlangen-Nürnberg is the trial sponsor within the European Union. To qualify for participation in the trial, investigators and their staff will undergo training prior to recruiting patients into the trial. The trial will be approved by appropriate review boards in each participating center. This trial will be monitored regularly by a qualified monitor from the sponsor or an organization commissioned by the sponsor, according to GCP guidelines and the respective standard operating procedure.

Funding

EuroHYP-1 has received funding from the European Union’s Seventh Framework Program (FP7/2007–2013) under grant agreement nº 278709. The prefunding phase was supported by an unconditional grant from W. Hacke from his 2009 Max Jarecki and Mihara awards. HBvdW is supported by a grant from the Dutch Heart Foundation (2010T075). PMB is Stroke Association Professor of Stroke Medicine.

Summary and conclusions

One of the reasons for the recurrent failure of allegedly neuroprotective strategies to improve functional outcome in patients may be that most inhibit only a single step in the chain of events leading to cell death. By contrast, hypothermia affects a wide range of cellular death mechanisms, including energy depletion, disruption of the blood-brain barrier, free radical formation, excitotoxicity, and inflammation (4). The proof of principle for therapeutic hypothermia has been provided in randomized trials in patients with postanoxic encephalopathy after cardiac arrest (5), although the validity of trials’ results have been questioned (13). In addition, the optimal target temperature and the effects of delay to treatment are still uncertain (14,15). Next to novel perfusion strategies, therapeutic hypothermia may therefore represent the best chance for patients with acute ischemic stroke patients to gain major benefit in terms of functional outcome.

EuroHYP-1 will test this assumption, parallel to the American Intravascular Cooling in the Treatment of Stroke 2/3 Trial (ICTuS2/3; http://clinicaltrials.gov/show/NCT01123161).

The complete EuroHYP-1 protocol may be obtained from the study sponsor and can be accessed at the study website http://www.eurohyp1.eu. No rights can be derived from this summarized version.

References